Clinical Trial Search

Primary: Number of Participants With Systemic Drug-related Adverse Events — 3; 0 participants

Primary: Change From Baseline in CRT as Measured by SD-OCT on Day 29 — 44.0 μm

Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001

Primary: Summary of Adverse Events — 57; 16; 47; 4 participants

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Best Corrected Visual Acuity (BCVA) — 7.0 letters

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs) — 0; 0; 0; 0 Participants

Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters

Primary: Best Corrected Visual Acuity (BCVA) — 2.0 letters

Primary: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.4; 95.1; 95.9; 95.1 percentage of patients

Primary: Visual Acuity (VA) — 8.51; 8.72; 8.67; 8.93 lines of VA

Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 — 1.17; 1.05; 0.87 score on a scale — p=0.919

Primary: Change From Baseline at Month 1 in Central Subfield Thickness (CSFT) as Measured by Spectral Domain Ocular Coherence Tomography (SD-OCT) — -142.3; -181.6; -175.6; -174.9…

Primary: Change in Mean Central Subfield Thickness (CST) — -36.6; 1.7 microns — p=0.04

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24 — 0.024; 0.050; 0.363; 0.285 mm — p=0.236

Primary: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.42; 95.62; 96.27; 95.56 Percentage of participants

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…

Primary: Visual Acuity - Continuous — -5.5 Letter seen on eye chart

Primary: Change in Edema From Baseline to Month 6 Central Subfield Thickness ) on Heidelberg Optical Coherence Topography — -30.0; 7.5 microns

Primary: Change From Baseline Visual Acuity at 6 Months — 3.8 number of letters

Primary: Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability — 0; 0; 1 Participants

Primary: Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline. — 59.4; 63.4; 71.1 Percentage of Participants

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: Mean Central Subfield Thickness (CST) — 422.9; 419.7; 364.5; 346.7 microns

Primary: The Percentage of Patients With Less Than 15 Letters of ETDRS Visual Loss at 12 Months. — 22; 14 percentage of participants